Esterified Arachidonate Research Articles

Influence of cellular arachidonic acid levels on phospholipid remodeling and CoA-independent transacylase activity in human monocytes and U937 cells

The availability of free arachidonic acid (AA) constitutes a limiting step in the synthesis of biologically active eicosanoids. Free AA levels in cells are regulated by a deacylation/reacylation cycle of membrane phospholipids, the so-called Lands cycle, as well as by further remodeling reactions catalyzed by CoA-independent transacylase. In this work, we have comparatively investigated the process of AA incorporation into and remodeling between the various phospholipid classes of human monocytes and monocyte-like U937 cells. AA incorporation into phospholipids was similar in both cell types, but a marked difference in the rate of remodeling was appreciated. U937 cells remodeled AA at a much faster rate than human monocytes. This difference was found not to be related to the differentiation state of the U937 cells, but rather to the low levels of esterified arachidonate found in U937 cells compared to human monocytes. Incubating the U937 cells in AA-rich media increased the cellular content of this fatty acid and led to a substantial decrease of the rate of phospholipid AA remodeling, which was due to reduced CoA-independent transacylase activity. Collectively, these findings provide the first evidence that cellular AA levels determine the amount of CoA-independent transacylase activity expressed by cells and provide support to the notion that CoA-IT is a major regulator of AA metabolism in human monocytes.

Isoprostanes and other markers of peroxidation in atherosclerosis

Several lines of evidence suggest that reactive oxygen species play a role in the development of vasculopathies, including those that define atherosclerosis, hypertension and restenosis after angioplasty. Confused picture emerging from prospective clinical trials of anti-oxidants may reflect inadequacy of traditional indices of lipid peroxidation in the recruitment of appropriate patients and in guiding the selection of the appropriate dose of anti-oxidant to be tested. Ex vivo indices of oxidant stress could have questionable veracity in assessing the actual rate of lipid peroxidation in vivo. The measurement of F2-isoprostanes (F2-iPs), formed non-enzimatically through free radical catalysed attack on esterified arachidonate, provides a reliable tool for identifyng populations with enhanced rates of lipid peroxidation. Enhanced formation of F2-iPs, together with increased in vivo platelet activation, has been reported in association with several cardiovascular risk factors. Thus, it has been suggested that F2-iPs may transduce oxidant stress-dependent platelet activation. Measurements of 8-iso-PGF2α, an abundant F2-iP formed in vivo, in urine may provide sensitive biochemical end-points for the assessment of the oxidant status of the patient and the true efficacy of anti-oxidant therapies. The incorporation of such biochemical end-points in clinical trials may help to verify the reliability of the oxidative modification hypothesis in the development of atheroscelerosis.

Degree of heteroplasmy reflects oxidant damage in a large family with the mitochondrial DNA A8344G mutation

Mitochondria are the source of most oxygen-derived free radicals. Mutations in mitochondrial DNA can impair mitochondrial electron transport resulting in decreased ATP production and increased free radical-induced oxidant injury. The specific mitochondrial DNA mutation A8344G alters the TΨC loop or the mitochondrial tRNA for lysine. We investigated a large five-generational family harboring this mutation to determine whether the degree of heteroplasmy (proportion of mutated mitochondrial genomes) for the mtA8344G mutation correlated with a marker of oxidant damage. We measured F 2-isoprostanes because they are specific and reliable markers of oxidant injury formed when free radicals attack esterified arachidonate in cell membranes. Family members with high heteroplasmy (>40%) had significantly higher F 2-isoprostane levels (62 ± 39 pg/ml) than those with lower heteroplasmy (33 ± 13 pg/ml, P < 0.001). The degree of heteroplasmy for the mtA8344G mutation in this family correlated positively with F 2-isoprostane levels ( P = 0.03). This study highlights the underappreciated role free radicals play in the complex pathophysiology of inherited mitochondrial DNA disorders. The most important novel finding from this family is that some currently asymptomatic individuals with moderate heteroplasmy have evidence of ongoing free-radical mediated oxidant injury.

Electrospray ionization tandem mass spectrometry of glycerophosphoethanolamine plasmalogen phospholipids

Collision-induced dissociation (CID) of the [M + H]+ of glycerophospholipids typically results in abundant fragment ions that are related to the polar head group or loss of the polar head group. An exception to this general rule occurs for glycerophosphoethanolamines (GPEtn), which are a class of phospholipids that can have an acyl, 1-O-alkyl, or 1-O-alk-1'-enyl group as a substituent at the sn-1 position. The CID of the [M + H]+ of diacyl-GPEtn typically results in the expected loss of the phosphoethanolamine head group (141 Da). Therefore, constant neutral loss of 141 Da has been used as a diagnostic tool for the determination of GPEtn species in complex lipid mixtures. One disadvantage in using constant neutral loss of 141 Da in order to determine GPEtn content in lipid mixtures is that plasmalogen GPEtn does not undergo neutral loss of phosphoethanolamine to the same extent as diacyl-GPEtn. The current studies have used positive ion mode electrospray tandem mass spectrometry to study the collision-induced dissociation of various GPEtn plasmalogens present in the phospholipid membranes of human neutrophils. The CID of the [M + H]+ of plasmalogen GPEtn resulted in two prominent fragment ions; one that was characteristic of the sn-1 position and one that was characteristic of the sn-2 position. These two ions were used to detect specific molecular species of GPEtn containing esterified arachidonate (precursors of m/z 361) present in the human neutrophil.

Brain lipid metabolism in the cPLA2 knockout mouse

We examined brain phospholipid metabolism in mice in which the cytosolic phospholipase A(2) (cPLA(2,) Type IV, 85 kDa) was knocked out (cPLA(2)(-/-) mice). Compared with controls, these mice demonstrated altered brain concentrations of several phospholipids, reduced esterified linoleate, arachidonate, and docosahexaenoate in choline glycerophospholipid, and reduced esterified arachidonate in phosphatidylinositol. Unanesthetized cPLA(2)(-/-) mice had reduced rates of incorporation of unlabeled arachidonate from plasma and from the brain arachidonoyl-CoA pool into ethanolamine glycerophospholipid and choline glycerophospholipid, but elevated rates into phosphatidylinositol. These differences corresponded to altered turnover and metabolic loss of esterified brain arachidonate. These results suggests that cPLA(2) is necessary to maintain normal brain concentrations of phospholipids and of their esterified polyunsaturated fatty acids. Reduced esterified arachidonate and docosahexaenoate may account for the resistance of the cPLA(2)(-/-) mouse to middle cerebral artery occlusion, and should influence membrane fluidity, neuroinflammation, signal transduction, and other brain processes.

Peroxidation of arachidonate containing plasmenyl glycerophosphocholine: facile oxidation of esterified arachidonate at carbon-5

Oxidation of 1-O-hexadec-1′-enyl-arachidonoyl glycerophosphocholine (16:0p/20:4-GPC) by hydroxyl radical generated from Cu(II)/H 2O 2 was found to yield major products corresponding to free carboxylic acids of 5-hydroxyeicosatetraenoic acid and several 5,12-dihydroxyeicosatetraenoic acid. These products were characterized by electrospray tandem mass spectrometry based upon characteristic product ion spectra, as well as HPLC retention time. Several products were found to be biologically active in terms of elevating neutrophil intracellular calcium ion concentration. When mixed micelles of 16:0p/20:4-GPC were treated with Cu(II)/H 2O 2, oxidation of the arachidonate esterified to the plasmalogen glycerophosphocholine lipid resulted in the most abundant products oxidized at carbon-5 of esterified arachidonate, but free carboxylic acid products were not formed. The mechanism of formation of these oxidized products is suggested to involve a cooperation between the sn-1 vinyl ether substituent and the arachidonoyl substituent at sn-2 of the glycerophospholipid to direct oxidation of the arachidonate ester at carbon-5. Since arachidonic acid is found in high abundance within most plasmalogen glycerophospholipids, the susceptibility of plasmalogens to free radical oxidation likely involves concomitant oxidation of the arachidonyl radyl group esterified at the sn-2 position.

The questionable role of a microsomal delta8 acyl-coA-dependent desaturase in the biosynthesis of polyunsaturated fatty acids.

Several experimental approaches were used to determine whether rat liver and testes express an acyl-CoA-dependent delta8 desaturase. When [1-14C]5,11,14-eicosatrienoic acid was injected via the tail vein, or directly into testes, it was incorporated into liver and testes phospholipids, but it was not metabolized to other labeled fatty acids. When [1-14C]11,14-eicosadienoic acid was injected, via the tail vein or directly into testes, or incubated with microsomes from both tissues, it was only metabolized to 5,11,14-eicosatrienoic acid. When ethyl 5,5,11,11,14,14-d6-5,11,14-eicosatrienoate was fed to rats maintained on a diet devoid of fat, it primarily replaced esterified 5,8,11-eicosatrienoic acid, but not arachidonic acid. No labeled linoleate or arachidonate were detected. Dietary ethyl linoleate and ethyl 19,19,20,20-d4-1,2-13C-11,14-eicosadienoate were about equally effective as precursors of esterified arachidonate. The doubly labeled 11,14-eicosadienoate was metabolized primarily by conversion to 17,17,18,18-d4-9,12-ocatdecadienoic acid, followed by its conversion to yield esterified arachidonate, with a mass four units greater than endogenous arachidonate. In addition, the doubly labeled substrate gave rise to a small amount of arachidonate, six mass units greater than endogenous arachidonate. No evidence was obtained, with the radiolabeled substrates, for the presence of a delta8 desaturase. However, the presence of an ion, six mass units greater than endogenous arachidonate when doubly labeled 11,14-eicosadienoate was fed, suggests that a small amount of the substrate may have been metabolized by the sequential use of delta8 and delta5 desaturases.

Regulation of the biosynthesis of 4,7,10,13,16-docosapentaenoic acid.

It is now established that fatty acid 7,10,13,16-22:4 is metabolized into 4,7,10,13,16-22:5 as follows: 7,10,13,16-22:4-->9,12,15, 18-24:4-->6,9,12,15,18-24:5-->4,7,10,13,16-22:5. Neither C24 fatty acid was esterified to 1-acyl-sn-glycero-3-phosphocholine (1-acyl-GPC) by microsomes, whereas the rates of esterification of 4, 7,10,13,16-22:5, 7,10,13,16-22:4 and 5,8,11,14-20:4 were respectively 135, 18 and 160 nmol/min per mg of microsomal protein. About four times as much acid-soluble radioactivity was produced when peroxisomes were incubated with [3-14C]9,12,15,18-24:4 compared with 6,9,12,15,18-24:5. Only [1-14C]7,10,13,16-22:4 accumulated when [3-14C]9,12,15,18-24:4 was the substrate, but both 4,7,10,13,16-22:5 and 2-trans-4,7,10,13,16-22:6 were produced from [3-14C]6,9,12,15, 18-24:5. When the two C24 fatty acids were incubated with peroxisomes, microsomes and 1-acyl-GPC there was a decrease in the production of acid-soluble radioactivity from [3-14C]6,9,12,15, 18-24:5, but not from [3-14C]9,12,15,18-24:4. The preferential fate of [1-14C]4,7,10,13,16-22:5, when it was produced, was to move out of peroxisomes for esterification into the acceptor, whereas only small amounts of 7,10,13,16-22:4 were esterified. By using 2H-labelled 9,12,15,18-24:4 it was shown that, when 7,10,13,16-22:4 was produced, its primary metabolic fate was degradation to yield esterified arachidonate. Collectively, the results show that an inverse relationship exists between rates of peroxisomal beta-oxidation and of esterification into 1-acyl-GPC by microsomes. Most importantly, when a fatty acid is produced with its first double bond at position 4, it preferentially moves out of peroxisomes for esterification to 1-acyl-GPC by microsomes, rather than being degraded further via a cycle of beta-oxidation that requires NADPH-dependent 2,4-dienoyl-CoA reductase.

Mechanisms of platelet-activating factor-induced lipid body formation: requisite roles for 5-lipoxygenase and de novo protein synthesis in the compartmentalization of neutrophil lipids.

Lipid bodies, lipid rich cytoplasmic inclusions, are characteristically abundant in vivo in leukocytes associated with inflammation. Because lipid bodies are potential reservoirs of esterified arachidonate and sites at which eicosanoid-forming enzymes may localize, we evaluated mechanisms of lipid body formation in neutrophils (PMN). Among receptor-mediated agonists, platelet activating factor (PAF), but not C5a, formyl-methyl-phenylalanine, interleukin 8, or leukotriene (LT) B4, induced the rapid formation of lipid bodies in PMN. This action of PAF was receptor mediated, as it was dose dependently inhibited by the PAF receptor antagonist WEB 2086 and blocked by pertussis toxin. Lipid body induction by PAF required 5-lipoxygenase (LO) activity and was inhibited by the 5-lipoxygenase-activating protein antagonist MK 886 and the 5-LO inhibitor zileuton, but not by cyclooxygenase inhibitors. Corroborating the dependency of PAF-induced lipid body formation on 5-LO, PMN and macrophages from wild-type mice, but not from 5-LO genetically deficient mice, formed lipid bodies on exposure to PAF both in vitro and in vivo within the pleural cavity. The 5-LO product inducing lipid body formation was not LTB4 but was 5(S)-hydroxyeicosatetraenoic acid [5(S)-HETE], which was active at 10-fold lower concentrations than PAF and was also inhibited by pertussis toxin but not by zileuton or WEB 2086. Furthermore, 5-HETE was equally effective in inducing lipid body formation in both wild-type and 5-LO genetically deficient mice. Both PAF- and 5(S)-HETE-induced lipid body formation were inhibited by protein kinase C (PKC) inhibitors staurosporine and chelerythrine, the phospholipase C (PLC) inhibitors D609 and U-73122, and by actinomycin D and cycloheximide. Prior stimulation of human PMN with PAF to form lipid bodies enhanced eicosanoid production in response to submaximal stimulation with the calcium ionophore A23187; and the levels of both prostaglandin (PG) E2 and LTB4 correlated with the number of lipid bodies. Furthermore, pretreatment of cells with actinomycin D or cycloheximide inhibited not only the induction of lipid body formation by PAF, but also the PAF-induced "priming" for enhanced PGE2 and LTB4 in PMN. Thus, the compartmentalization of lipids to form lipid bodies in PMN is dependent on specific cellular responses that can be PAF receptor mediated, involves signaling through 5-LO to form 5-HETE and then through PKC and PLC, and requires new protein synthesis. Since increases in lipid body numbers correlated with priming for enhanced PGE2 and LTB4 production in PMN, the induction of lipid bodies may have a role in the formation of eicosanoid mediators by leukocytes involved in inflammation.

Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor.

Lipoxin A4 (LXA4) triggers selective responses with human neutrophils that are pertussis toxin sensitive and binds to high affinity receptors (Kd = 0.5 +/- 0.3 nM) that are modulated by stable analogues of guanosine 5'-triphosphate (GTP). Here, we characterized [11,12-(3)]LXA4 specific binding with neutrophil granule and plasma membranes, which each display high affinity binding sites (Kd = 0.7 +/- 0.1 nM) that were regulated by GTP gamma S. Since functional LXA4 receptors are inducible in HL-60 cells, we tested orphan cDNAs encoding 7-transmembrane region receptors cloned from these cells for their ability to bind and signal with LXA4. Chinese hamster ovary (CHO) cells transfected with the orphan receptor cDNA (pINF114) displayed specific 3H-LXA4 high affinity binding (1.7 nM). When displacement of LXA4 binding with pINF114-transfected CHO cells was tested with other eicosanoids, including LXB4, leukotriene D4 (LTD4), LTB4, or prostaglandin E2, only LTD4 competed with LXA4, giving a Ki of 80 nM. In transfected CHO cells, LXA4 also stimulated GTPase activity and provoked the release of esterified arachidonate, which proved to be pertussis toxin sensitive. These results indicate that pINF114 cDNA encodes a 7-transmembrane region-containing protein that displays high affinity for 3H-LXA4 and transmits LXA4-induced signals. Together, they suggest that the encoded protein is a candidate for a LXA4 receptor in myeloid cells.

A comparison of the specific activities of linoleate and arachidonate in liver, heart and kidney phospholipids after feeding rats ethyl linoleate-9,10,12,13- d4

In order to determine how dietary linoleate is metabolized, rats were maintained on a chemically defined diet containing 1.6% ethyl linoleate. After 5 weeks the linoleate was replaced by an equal amount of ethyl 9,10,12,13- d 4-linoleate. The animals were killed 3 days later and the molar percentage of d 4-linoleate and d 4-arachidonate were quantified in liver, heart and kidne phospholipids. In liver, 54 and 22.8 mol% respectively of the esterified linoleate and arachidonate was deuteriated. The lower specific activity of arachidonate versus linoleate suggests that desaturation of linoleate, by a 6-desaturase, is not only rate limiting for synthesis of arachidonate but that the amount of newly synthesized arachidonate is insufficient by itself to maintain steady state levels of esterified arachidonate. The molar fraction of deuteriated linoleate in heart and kidney phospholipids was respectively 35 and 37.4%. These values are lower than for liver phospholipids but it appears there is adequate dietary linoleate available in these tissues for the synthesis of arachidonate. However, of the esterified arachidonate in heart and kidney phospholipids only 4.2 and 8.6 mol% respectively was deuteriated. Our results suggest that arachidonate is made in liver and transported to heart and kidney.

Metabolism of [ 14c]arachidonic acid-labeled lipids in quiescent and oag-stimulated ascites tumor cells

1. l. A rapid uptake and esterification of [ 14C]arachidonic acid during the first 4 hr of cultivation of ascites cells in serum-deprived medium was observed followed by a fast turnover of the fatty acid. 2. 2. Labeling and turnover of esterified arachidonate in individual phospholipid classes was in the order: phosphatidylcholine (PC)> phosphatidylinositol (PI) > phosphatidylinositol-4-phosphate (PIP) and -4,5-bisphosphate (PIP 2) > phosphatidylethanolamine (PE) > PE-plasmalogens. 3. 3. In cells stimulated with l-oleoyl-2-acetyl- sn-glycerol a transient course of arachidonic acid incorporation into PC, PI, PIP and PIP, was determined peaking 30 min after stimulation, indicating both esterification and release under these conditions. 4. 4. The release of arachidonate was blocked by quinacrine which is a specific inhibitor of phospholipase A 2.

Cytoplasmic lipid bodies of neutrophils: formation induced by cis-unsaturated fatty acids and mediated by protein kinase C.

Lipid bodies, nonmembrane-bound cytoplasmic inclusions, serve as repositories of esterified arachidonate and are increased in cells associated with inflammatory reactions. We have evaluated stimuli and mechanisms responsible for lipid body formation within human polymorphonuclear leukocytes (PMNs). Arachidonic acid and oleic acid stimulated dose-dependent formation of lipid bodies over 0.5-1 h. Other C20 and C18 fatty acids were less active and demonstrated rank orders as follows: cis-unsaturated fatty acids were much more active than trans-fatty acids, and activity diminished with decreasing numbers of double bonds. Lipid bodies elicited in vitro with cis-fatty acids were ultrastructurally identical to lipid bodies present in PMNs in vivo. Lipid body induction was not because of fatty acid-elicited oxidants or fatty acid-induced ATP depletion. Cis-fatty acid-induced activation of protein kinase C (PKC) was involved in lipid body formation as evidenced by the capacity of other PKC activators, 1-oleoyl-2-acetyl-glycerol and two active phorbol esters, phorbol myristate acetate, and phorbol 12,13 dibutyrate, but not an inactive phorbol, to induce lipid body formation. The PKC inhibitor, 1-O-hexadecyl-2-O-methyl-glycerol, inhibited PMN lipid body formation induced by oleic and arachidonic acids and by 1-oleoyl-2-acetyl-glycerol and phorbol myristate acetate. Other PKC inhibitors (staurosporine, H-7) also inhibited lipid body formation. Formation of lipid bodies in PMNs is a specific cellular response, stimulated by cis-fatty acids and diglycerides and apparently mediated by PKC, which results in the mobilization and deposition of lipids within discrete, ultrastructurally defined cytoplasmic domains.

Blockade of receptor-mediated cyclic GMP formation by hydroxyeicosatetraenoic acid.

Receptor-mediated cyclic GMP formation in N1E-115 murine neuroblastoma cells appears to involve oxidative metabolism of arachidonic acid. Evidence in support of this includes the blockade of this response by lipoxygenase inhibitors, e.g., eicosatetraynoic acid (ETYA) or other metabolic perturbants, e.g., methylene blue. It was recently discovered that the lipoxygenase products 15-hydroxyeicosatetraenoic (15-HETE) acid and 12-HETE, like ETYA, were inhibitors of M1 muscarinic receptor-mediated cyclic GMP formation. In the present report, the effects of monoHETEs are explored in more detail, particularly with regard to the function of the muscarinic receptor. Like 12-HETE and 15-HETE (IC50 = 13 and 11 microM, respectively), 5-HETE inhibited the cyclic GMP response to the muscarinic receptor (IC50 = 10 microM). All three of these monoHETEs were shown also to be inhibitors of the cyclic GMP responses to receptors stimulated by carbachol, histamine, thrombin, neurotensin, and bradykinin. 15-HETE was shown to inhibit the muscarinic receptor-mediated response in a complex manner (apparent noncompetitive and uncompetitive components; IC50 = 18 and 2 microM, respectively). 15-HETE did not inhibit either the M1 muscarinic receptor-stimulated release of [3H]inositol phosphates from cellular phospholipids or the M2 muscarinic receptor-mediated inhibition of hormone (prostaglandin E1)-induced AMP formation. It seemed possible that the monoHETEs could enter into biochemical pathways for arachidonate in N1E-115 cells. [3H]Arachidonate and the three [3H]-monoHETEs all rapidly labeled the membrane lipids of intact N1E-115 cells, with each [3H]eicosanoid producing a unique labeling profile. [3H]15-HETE labeling was noteworthy in that 85% of the label found in the phospholipids was in phosphatidylinositol (PI;t1/2 to steady state = 3 min). Exogenous 15-HETE inhibited the labeling of PI by [3H]arachidonate (IC50 = 28 microM) and elevated unesterified [3H]arachidonate levels. Thus, the mechanism of blockade of receptor-mediated cyclic GMP responses by monoHETEs is likely to be more complex than the simple inhibition of cytosolic mechanisms, e.g., generation of a putative second messenger by lipoxygenase, and may involve also alterations of membrane function accompanying the redistributions of esterified arachidonate.

Oxidation of esterified arachidonate by rat liver microsomes

Rat hepatic microsomal lipids were labeled with [U- 14C]arachidonate and were then peroxidized by an NADPH-dependent iron pyrophosphate system. The extent of peroxidation was quantified by malondialdehyde production and arachidonate disappearance. Following peroxidation, the microsomes were centrifuged and the oxidation products were extracted from the supernatant. A linear correlation was found between malondialdehyde production and radioactivity in the supernatant. The pellet was treated with phospholipase A 2 to cleave peroxidized products from the phospholipids. Exogenous phospholipase A 2 activity was reduced by lipid peroxidation but this was overcome by using a high concentration of the enzyme along with the addition of melittin. The deesterified lipid products from the pellet were extracted and the fragments from the supernatant and the hydrolyzed pellet were separated by reverse-phase HPLC. Several different labeled polar products which coeluted with carbonyl-containing compounds ( A 285 and hydrazone formation) were found in both the supernatant and the pellet. In addition, many other carbonyl compounds were found which were not arachidonatederived. The elution pattern of the fragments after 2 and 15 min of peroxidation were qualitatively identical; i.e., no product-precursor relationship was seen. This, along with the observation that peroxidation quickly ceased upon the rapid depletion of NADPH, suggests that propagation did not occur. Finally, the data indicate that cytochrome P-450 is not involved in microsomal lipid peroxidation since product formation is unaffected by the presence of carbon monoxide (80%) and no oxidation of phospholipid arachidonate occurs in the absence of iron.

Coenzyme A-mediated arachidonic acid transacylation in human platelets.

Platelet membranes contain two distinct transacylase activities catalyzing the synthesis of arachidonoyl phosphatides by acylation of added lysophosphatides with endogenous esterified arachidonate. In the absence of CoA, arachidonate is incorporated only into ethanolamine lysophosphatides with a high preference for the plasmalogen form (Kramer, R. M., and Deykin, D. (1983) J. Biol. Chem. 258, 13806-13811). In the presence of CoA, however, lysophospholipids are acylated in the order 1-acyl-lysophosphatidylserine greater than 1-acyl-lysophosphatidylethanolamine greater than 1-acyl-lysophosphatidylinositol. The CoA-mediated transacylation reaction was characterized with 1-acyl-lysophosphatidylserine as acyl acceptor. It was highly specific for arachidonate and preferentially used phosphatidylcholine as the arachidonoyl donor. This enzymatic pathway may be part of a deacylation-transacylation cycle for remodeling of phospholipids synthesized de novo (according to the Lands pathway) representing a mechanism for enrichment of phospholipids with arachidonic acid.

Different pools of esterified arachidonic acid in rabbit kidney medulla: relationship to Ca2+-stimulated prostaglandin biosynthesis.

We investigated the effect of Ca2+ ions on renal medulla metabolism of endogenous esterified arachidonic acid in contrast to that of radioactive arachidonate incorporated into medullary lipids. Some striking differences between the release of unlabeled prostaglandin E2 and of 14C-labeled prostaglandin E2 and arachidonic acid were seen in incubations in absence or presence of Ca2+ ions. These differences indicated that exogenous [14C] arachidonate incubated with medulla slices is incorporated into both Ca2+-sensitive and Ca2+-insensitive lipid pools of esterified arachidonate and furthermore, the Ca2+-sensitive pool is itself heterogeneous and consists of at least 2 functionally different lipid pools of esterified arachidonate. The first Ca2+-sensitive pool is characterized by a higher arachidonate turnover rate and incorporates more rapidly added radioactive arachidonate. The acylhydrolase activity which releases arachidonate from this pool is not efficiently coupled to prostaglandin endoperoxide synthase. In contrast, the second Ca2+-sensitive lipid pool has a slower arachidonate turnover rate and, consequently, a slower incorporation of added 14C-acid. The acylhydrolase activity associated with this pool is more tightly coupled to prostaglandin endoperoxide synthase, so that a higher portion of released arachidonate is converted to prostaglandin E2. Studies on arachidonic acid metabolic transformations using exogenously radioactive free acid added to tissues should therefore be interpreted with caution because the results obtained may not reflect accurately the metabolic fate of endogenous, lipid-esterified arachidonate which is released and metabolized under physiological conditions in vivo.

Studies on the arachidonic acid cascade—I: Inhibition of phospholipase A 2in vitro and in vivo by several novel series of inhibitor compounds

A series of compounds have been discovered which are potent inhibitors in vitro of hog pancreas, cobra venom, and bee venom phospholipase A 2. Collagen-induced aggregation of human platelets was prevented by representatives of this series. The inhibition was reversed by aggregatory concentrations of arachidonate, indicating the hydrolysis of esterified arachidonate had been prevented. In the isolated perfused guinea pig lung sensitized to ovalbumin, the release of prostanoids, resulting from a challenge dose of the antigen, was prevented by exemplars of these compounds. Subsequent administration of arachidonate in the presence of the inhibitor resulted in full prostanoid synthesis and secretion, again indicating that the block was at the phospholipase level. Administration of some of these compounds to guinea pigs by subcutaneous or intraperitoneal routes delayed the onset, and decreased the severity, of erythema induced in depilitated skin by the controlled application of ultraviolet light. This result was, also, consistent with phospholipase A 2 inhibition. Kinetic experiments with hog pancreas phospholipase A 2 demonstrated that, with representatives of this series, the inhibition induced was noncompetitive, and appropriate dissociation constants have been calculated.

Incorporation of [ 14]arachidonate in pig thyroid lipids and prostaglandins

In pig and sheep thyroid, the arachidonate content of phosphatidylinositol (14.3–17.5%) is much higher than in the other phospholipids. In the thyroid, phosphatidylinositol seems to play an important role in the biosynthesis of prostaglandins. In neutral thyroid lipids, the arachidonate content is much higher in diacylglycerols (15.8%) than in monoacylglycerols (2.9%) or triacylglycerols (4.2%). However, the most important pool of esterified arachidonate is triacylglycerols (1030 nmol of arachidonate/g tissue). Arachidonate represents a very small part of total free fatty acids measured in the presence of albumin and indomethacin (0.65% or 16.4 nmol/g tissue). Thyrotropin (50 munits/ml) causes after 1 h a 2-fold increase in the level of free arachidonate (37.3 nmol/g tissue). Pig thyroid slices rapidly take up [ 14C] arachidonate and incorporate it into neutral lipids and phospholipids. Specific activity of phosphatidylinositol is 3-fold higher than that of phosphatidylcholine after an hour incubation. Specific activity of diacylglycerols is 8-fold higher than that of triacylglycerols. Thyrotropin (50 munits/ml) causes a significant decrease (32–33%) of incorporation of radioactivity in lipids as compared with standard incubation. This result is compatible with the isotopic dilution of the labeled [ 14C]arachidonate by nonradioactive arachidonate liberated in the incubation medium under thyrotropin action. Slices and homogenates of pig thyroid weakly convert [ 14C] arachidonate to prostaglandins E 2 and F 2α (1–2%). Thyrotropin (50 munits/ml) always diminishes the conversion of radioactivity to prostaglandins as compared with standard incubation. This result is compatible with the above-mentioned hypothesis.